Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd. develops cancer immunotherapy programs using its AI/ML-powered Unigen computational discovery capabilities to identify drug targets and biological pathways. News about CGEN commonly covers clinical and preclinical immuno-oncology programs, including COM701, COM902, rilvegostomig and GS-0321, as well as updates tied to immune-checkpoint targets such as PVRIG, TIGIT and IL-18 binding protein.
Recurring company developments include quarterly and annual financial results, corporate updates, scientific conference presentations, clinical data disclosures, partnership activity with AstraZeneca and Gilead, royalty and license arrangements, and board or leadership changes. Compugen's ordinary shares trade on Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN.
Compugen (NASDAQ:CGEN) reported Q1 2026 results and clinical progress. Cash, cash equivalents, deposits and securities totaled $134.9 million as of March 31, 2026, with no debt and cash runway expected to fund operations into 2029.
Q1 2026 revenue was $2.2 million, R&D expenses $6.9 million, G&A expenses $2.3 million, and net loss $7.7 million ($0.08 per share). The COM701 MAIA-ovarian trial is enrolling in the U.S., Israel and France, with interim analysis targeted by Q1 2027. Partner AstraZeneca is advancing rilvegostomig in 11 Phase 3 trials, and the Gilead-partnered GS-0321 Phase 1 trial is progressing. Partnerships with AstraZeneca and Gilead offer about $1 billion in potential milestones plus royalties.
Compugen (Nasdaq:CGEN), a clinical-stage cancer immunotherapy company using AI/ML for computational target discovery, will present at the 2026 Stifel Virtual Targeted Oncology Forum.
The management presentation is scheduled for May 19, 2026, 10:00–10:25 AM ET, with live webcast and replay via Compugen’s investor relations website.
Compugen (NASDAQ: CGEN) will release first quarter 2026 financial results on Monday, May 18, 2026 before U.S. markets open. Management will host a conference call and webcast at 8:30 AM ET to review results and provide a corporate update.
Telephone access: 1-866-744-5399 (U.S.) or +972-3-918-0644 (international). A live webcast and subsequent replay will be available via the company's investor website.
Compugen (NASDAQ: CGEN) will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 from 8:45–9:25 AM ET. A live webcast and a replay will be available on the company’s Investor Relations website at www.cgen.com.
Compugen (Nasdaq: CGEN) reported Q4 and full‑year 2025 results and a corporate update on March 2, 2026. Key items: $145.6M cash at year‑end, $65M upfront from AstraZeneca royalty monetization, expected cash runway into 2029, and CEO transition to Eran Ophir.
2025 revenue totaled $72.8M (Q4 $67.3M); net income was $35.3M for the year and Q4 net profit was $56.8M. Clinical progress includes COM701 MAIA‑ovarian and Gilead‑partnered GS‑0321 trials with MAIA interim analysis expected Q1 2027.
Compugen (NASDAQ: CGEN) said management will participate in two investor conferences in late Feb–early Mar 2026: Oppenheimer 36th Annual Healthcare Life Sciences Conference (virtual) on Feb 26, 2026 and Leerink Partners 2026 Global Healthcare Conference (Miami) on Mar 9, 2026.
Both events include fireside chats and 1x1 meetings; live webcasts and replays will be available on the company's investor relations events page at www.cgen.com.
Compugen (NASDAQ: CGEN) will release its fourth quarter and full year 2025 financial results on Monday, March 2, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:30 AM ET to review results and provide a corporate update.
Telephone access is available in the U.S. and internationally, and a replay will be posted on the company website after the live webcast.
Compugen (Nasdaq: CGEN) announced the appointment of Dr. Michele Holcomb as an independent director, effective February 11, 2026. Dr. Holcomb brings 30+ years in biotech, pharmaceuticals and healthcare services, including senior roles at Cardinal Health and Teva and a long tenure at McKinsey.
The company highlighted her experience in strategy, business development, partnerships and portfolio management as strengthening the board while Compugen advances multiple clinical programs, pharma partnerships and its AI/ML discovery platform.
Compugen (NASDAQ: CGEN) announced that it will monetize a portion of its rilvegostomig future royalties to AstraZeneca in a non-dilutive transaction dated Dec 17, 2025.
Key terms include an $65 million upfront payment and a potential $25 million milestone payment tied to the next BLA acceptance milestone, while Compugen retains the majority of future royalties and remains eligible for tiered royalties up to mid-single digits plus up to $195 million of potential regulatory and commercial milestones (including the $25 million).
Management says proceeds are expected to extend cash runway into 2029 to advance Compugen's clinical-stage immuno-oncology pipeline and partnered programs.
Compugen (NASDAQ: CGEN)/b) reported third-quarter 2025 results and a corporate update on Nov 10, 2025.Key items: $86.1M cash with runway into Q3 2027; Q3 revenue $1.9M versus $17.1M year-ago; net loss $6.98M ($0.07/share) vs prior quarter profit $1.28M. Clinical: pooled Phase 1 COM701 showed durable responses with median PFS 10.5 months in patients deriving benefit; MAIA-ovarian blinded randomized maintenance trial is enrolling in the U.S., Israel and France with interim analysis now estimated in Q1 2027. Corporate: GS-0321 (COM503) licensed to Gilead; partnership with AstraZeneca and Gilead carries >$1B potential milestones and royalties.